Zevra Therapeutics, Inc.
ZVRAZevra Therapeutics is a commercial-stage biotechnology company dedicated to developing and commercializing transformative therapies for rare diseases with significant unmet medical needs.
Earnings
Next report
Nov 4, 2026 (in 2 months)Valuation & ratios
Segments
Competitors
By market cap
By revenue growth
By net margin
Profile
Zevra Therapeutics is a commercial-stage biotechnology company dedicated to developing and commercializing transformative therapies for rare diseases with significant unmet medical needs. The company leverages a specialized infrastructure to advance late-stage clinical assets and manage a portfolio of marketed products for neurodegenerative and metabolic disorders. Its strategy combines internal development with inorganic growth through the acquisition of orphan drug assets.
A specialized rare-disease player with a commercial-stage foundation and a late-stage pipeline, utilizing Priority Review Vouchers and orphan designations to maintain a competitive edge.
FAQ
- What is Zevra Therapeutics, Inc.'s market cap?
- Zevra Therapeutics, Inc. (ZVRA) has a market capitalization of $691.8M and trades on NASDAQ.
- What is Zevra Therapeutics, Inc.'s revenue and profitability?
- Zevra Therapeutics, Inc. generated $136.1M in trailing twelve-month revenue with net income of $58.3M, representing a net margin of 42.8%. Gross margin stands at 95.5%, with free cash flow of $10.8M. The latest reported period is Q2 2026.
- Who are Zevra Therapeutics, Inc.'s competitors?
- Zevra Therapeutics, Inc.'s key competitors include Ultragenyx Pharmaceutical, BioMarin Pharmaceutical, Fulcrum Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Zevra Therapeutics, Inc. partner with?
- Zevra Therapeutics, Inc.'s notable partners include European Medicines Agency, U.S. Food and Drug Administration.
- What subsidiaries does Zevra Therapeutics, Inc. have?
- Zevra Therapeutics, Inc.'s subsidiaries include Acer Therapeutics, Inc., Orphazyme A/S.
- Where is Zevra Therapeutics, Inc. headquartered?
- Zevra Therapeutics, Inc. is headquartered in United States of America and employs approximately 69 people. It has been publicly traded since 2015.
